The Defense Department yanked newly published clinical guidance on mandatory testosterone testing for troops just one day after posting it, even as officials insist the screening program remains on track.
The Defense Health Agency published its "Clinical Guidance for Health and Human Performance Optimization" on Wednesday, laying out a framework for blood-testing male service members age 30 and older for testosterone deficiency. By Thursday, the document had vanished from the DHA website, replaced by a notice stating the page had been "moved or been removed." A Pentagon official told The Hill that the guidance was pulled temporarily to allow for "updates."
The whiplash timeline raises a straightforward question: why publish guidance that needed immediate revision? The Pentagon offered no specifics on what required updating, and the unnamed official gave no timeline beyond saying final clinical guidance would arrive "shortly."
Defense Secretary Pete Hegseth first announced the testosterone screening and replacement therapy effort in July, framing it as a readiness imperative. His argument was blunt: the military spends heavily on hardware but underinvests in the physical optimization of the people who operate it.
"While we invest heavily in our weapon systems, platforms and gear, our most decisive tactical advantage will always be the individual warfighter. We have a sacred duty to maintain that advantage, which is why we must constantly look for new ways to optimize your performance, your resilience and your long-term health."
That was Hegseth in July. The initiative itself is sound in principle, identifying hormone deficiencies that degrade physical performance and treating them before they sideline warfighters. Testosterone replacement therapy is a legitimate medical intervention for men with clinically low levels, and the military has every reason to keep its force in peak condition.
Hegseth has faced broader friction inside the administration during his tenure. He was reportedly sidelined from Iran briefings in favor of Treasury Secretary Bessent, and Secretary of State Rubio blocked one of his Europe troop proposals ahead of a NATO summit. None of that changes whether the testosterone policy is good medicine, but it does explain why the rollout may have lacked the institutional follow-through a policy this visible demands.
The clinical document, cataloged as DHA-IPM-26-007, spelled out a tiered screening system. Male active-duty and reserve personnel age 30 and older would receive mandatory testosterone blood tests. Men under 30 would be tested only if a health professional flagged a concern or the service member requested it.
Service members diagnosed with low testosterone would receive treatments and additional screenings, though the specifics of those protocols were not detailed in available reporting. Female service members, meanwhile, would be asked whether they experienced disrupted menstrual cycles potentially linked to hormonal dysregulation, a provision that extended the guidance beyond the testosterone headline.
Hegseth has also moved aggressively on personnel matters during his time at the Pentagon, halting promotions for Army officers tied to ousted generals. The testosterone initiative fit a pattern of a defense secretary willing to push changes fast, sometimes faster than the bureaucracy could keep up.
Derek Griffith, who directs the program for research on men's health at the University of Pennsylvania, previously told The Hill that Hegseth's rationale for the screening program is not backed by the science. Griffith noted that only about 2 percent of the male population has low testosterone, a figure he said does not "suggest that this is a major problem." He did, however, acknowledge that testosterone replacement therapy can aid the health of men who genuinely suffer from the deficiency.
That 2 percent figure applies to the general male population, and it remains unclear whether military-age men, who face extreme physical demands, disrupted sleep cycles, and high stress, experience different rates. The Pentagon did not address that distinction in its public statements. If the military's own data showed a meaningful problem inside the ranks, releasing that evidence would have strengthened the case considerably. Its absence leaves a gap that critics like Griffith can fill.
The broader political environment around Hegseth has grown more complicated in recent months. Lawmakers in both parties have demanded oversight of his military personnel decisions, and reporting has surfaced friction with the White House over Iran policy. Against that backdrop, a botched document rollout, however minor in substance, gives opponents easy ammunition.
The Pentagon official stressed that the "Interim Guidance on Testosterone Deficiency Screenings for Active Duty and Reserve Component Personnel" remains in effect even after the clinical document was pulled. The official also said the department "remains committed to addressing hormone deficiencies, protecting the long-term health of its Service members and enabling peak operational performance."
But the full text of that interim guidance has not been made public in available reporting, leaving service members and the public unable to assess what screening obligations currently apply. The Pentagon has not explained the difference between the interim guidance and the clinical document that was posted and removed within 24 hours.
Reuters reported the rescission before The Hill's account, suggesting the reversal drew quick media attention. The DHA link now returns a "page not found" error, not exactly the image of a department executing a well-coordinated health initiative.
Reports of internal friction over Iran policy have added to questions about whether the Pentagon's leadership has the institutional bandwidth to manage detailed clinical rollouts alongside high-stakes geopolitical negotiations. That is a resource and focus problem, not a policy problem, but the result is the same when documents get published before they are ready.
The underlying idea, screening troops for hormone deficiencies and treating the ones who need it, is defensible. The military asks extraordinary physical performance from its people. Identifying treatable conditions that undermine that performance is common sense, not controversy.
What is not defensible is publishing clinical guidance on a Wednesday and pulling it on a Thursday with no explanation beyond "updates." That sequence suggests the document was not properly reviewed before it went live, a process failure inside the Defense Health Agency that hands critics an easy talking point and distracts from the policy's merits.
The Pentagon said final guidance is coming "shortly." If Hegseth and his team want this initiative to be taken seriously, "shortly" needs to mean days, not months, and the next version needs to stay posted longer than 24 hours.
A military that cannot manage its own document review process is not projecting the readiness its leaders keep promising.
